ABEONA THERAPEUTICS INC. Operating Cash Flow
ABEONA THERAPEUTICS INC. (ABEO) reported Operating Cash Flow of -$37.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$17.50M.
- ABEONA THERAPEUTICS INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$19.80M.
- ABEONA THERAPEUTICS INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$17.95M.
- ABEONA THERAPEUTICS INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$21.19M.
- ABEONA THERAPEUTICS INC. net cash provided by (used in) operating activities for fiscal 2025 was -$76.33M.
- ABEONA THERAPEUTICS INC. net cash provided by (used in) operating activities for fiscal 2024 was -$56.02M.
- ABEONA THERAPEUTICS INC. net cash provided by (used in) operating activities for fiscal 2023 was -$37.01M.
- ABEONA THERAPEUTICS INC. net cash provided by (used in) operating activities for fiscal 2022 was -$43.48M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$17.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$37.30M 10-Q · filed 2026-08-13 | -$55.25M derived: sum of 3 quarters · filed 2026-08-13 | -$76.44M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$19.80M 10-Q · filed 2026-05-13 | -$37.76M derived: sum of 2 quarters · filed 2026-05-13 | -$58.94M derived: sum of 3 quarters · filed 2026-05-13 | -$77.73M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | -$17.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$39.14M derived: sum of 2 quarters · filed 2026-03-17 | -$57.92M derived: sum of 3 quarters · filed 2026-08-13 | -$76.33M 10-K · filed 2026-03-17 | |
| 2025-09-30 | -$21.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$39.97M derived: sum of 2 quarters · filed 2026-08-13 | -$58.37M 10-Q · filed 2025-11-12 | -$74.93M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$18.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$37.19M 10-Q · filed 2026-08-13 | -$53.74M derived: sum of 3 quarters · filed 2026-08-13 | -$65.98M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$18.40M 10-Q · filed 2026-05-13 | -$34.96M derived: sum of 2 quarters · filed 2026-05-13 | -$47.20M derived: sum of 3 quarters · filed 2026-05-13 | -$59.88M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$16.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$28.79M derived: sum of 2 quarters · filed 2026-03-17 | -$41.48M derived: sum of 3 quarters · filed 2026-03-17 | -$56.02M 10-K · filed 2026-03-17 | |
| 2024-09-30 | -$12.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$24.92M derived: sum of 2 quarters · filed 2025-11-12 | -$39.46M 10-Q · filed 2025-11-12 | -$48.69M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$12.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$27.22M 10-Q · filed 2025-08-14 | -$36.46M derived: sum of 3 quarters · filed 2025-08-14 | -$42.20M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$14.54M 10-Q · filed 2025-05-15 | -$23.77M derived: sum of 2 quarters · filed 2025-05-15 | -$29.52M derived: sum of 3 quarters · filed 2025-05-15 | -$39.80M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$9.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$14.98M derived: sum of 2 quarters · filed 2025-03-20 | -$25.27M derived: sum of 3 quarters · filed 2025-03-20 | -$37.01M 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$5.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$16.03M derived: sum of 2 quarters · filed 2024-11-14 | -$27.77M 10-Q · filed 2024-11-14 | -$41.77M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$10.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$22.03M 10-Q · filed 2024-08-12 | -$36.02M derived: sum of 3 quarters · filed 2024-08-12 | -$42.81M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | -$11.74M 10-Q · filed 2024-05-15 | -$25.74M derived: sum of 2 quarters · filed 2024-05-15 | -$32.53M derived: sum of 3 quarters · filed 2024-05-15 | -$41.54M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$13.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$20.78M derived: sum of 2 quarters · filed 2024-03-18 | -$29.80M derived: sum of 3 quarters · filed 2024-03-18 | -$43.48M 10-K · filed 2024-03-18 | |
| 2022-09-30 | -$6.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$15.80M derived: sum of 2 quarters · filed 2023-11-13 | -$29.49M 10-Q · filed 2023-11-13 | -$59.75M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$9.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$22.70M 10-Q · filed 2023-08-08 | -$52.96M derived: sum of 3 quarters · filed 2023-08-08 | -$63.29M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$13.69M 10-Q · filed 2023-05-11 | -$43.94M derived: sum of 2 quarters · filed 2023-05-11 | -$54.28M derived: sum of 3 quarters · filed 2023-05-11 | -$65.77M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$30.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$40.59M derived: sum of 2 quarters · filed 2023-03-29 | -$52.08M derived: sum of 3 quarters · filed 2023-03-29 | -$65.67M 10-K · filed 2023-03-29 | |
| 2021-09-30 | -$10.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$21.82M derived: sum of 2 quarters · filed 2022-11-14 | -$35.41M 10-Q · filed 2022-11-14 | -$37.02M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$11.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$25.07M 10-Q · filed 2022-08-11 | -$26.68M derived: sum of 3 quarters · filed 2022-08-11 | -$37.39M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$13.59M 10-Q · filed 2022-05-13 | -$15.20M derived: sum of 2 quarters · filed 2022-05-13 | -$25.90M derived: sum of 3 quarters · filed 2022-05-13 | -$35.37M derived: sum of 4 quarters · filed 2022-05-13 | |
| 2020-12-31 | -$1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$12.31M derived: sum of 2 quarters · filed 2022-03-31 | -$21.79M derived: sum of 3 quarters · filed 2022-03-31 | -$35.02M 10-K · filed 2022-03-31 | |
| 2020-09-30 | -$10.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$20.18M derived: sum of 2 quarters · filed 2021-11-15 | -$33.41M 10-Q · filed 2021-11-15 | -$47.66M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | -$9.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | -$22.71M 10-Q · filed 2021-07-28 | -$36.95M derived: sum of 3 quarters · filed 2021-07-28 | -$55.21M derived: sum of 4 quarters · filed 2021-07-28 | |
| 2020-03-31 | -$13.23M 10-Q · filed 2021-05-17 | -$27.48M derived: sum of 2 quarters · filed 2021-05-17 | -$45.73M derived: sum of 3 quarters · filed 2021-05-17 | -$60.97M derived: sum of 4 quarters · filed 2021-05-17 | |
| 2019-12-31 | -$14.25M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | -$32.50M derived: sum of 2 quarters · filed 2021-03-24 | -$47.74M derived: sum of 3 quarters · filed 2021-03-24 | -$62.82M 10-K · filed 2021-03-24 | |
| 2019-09-30 | -$18.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$33.50M derived: sum of 2 quarters · filed 2020-11-09 | -$48.57M 10-Q · filed 2020-11-09 | -$65.54M derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | -$15.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$30.32M 10-Q · filed 2020-08-10 | -$47.29M derived: sum of 3 quarters · filed 2020-08-10 | -$56.33M derived: sum of 4 quarters · filed 2020-08-10 | |
| 2019-03-31 | -$15.08M 10-Q · filed 2020-05-06 | -$32.05M derived: sum of 2 quarters · filed 2020-05-06 | -$41.09M derived: sum of 3 quarters · filed 2020-05-06 | -$50.11M derived: sum of 4 quarters · filed 2020-05-06 | |
| 2018-12-31 | -$16.97M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$26.01M derived: sum of 2 quarters · filed 2020-03-16 | -$35.03M derived: sum of 3 quarters · filed 2020-03-16 | -$39.11M 10-K · filed 2020-03-16 | |
| 2018-09-30 | -$9.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$18.06M derived: sum of 2 quarters · filed 2019-11-12 | -$22.14M 10-Q · filed 2019-11-12 | -$27.19M derived: sum of 4 quarters · filed 2020-03-16 | |
| 2018-06-30 | -$9.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$13.10M 10-Q · filed 2019-08-09 | -$18.15M derived: sum of 3 quarters · filed 2020-03-16 | -$24.92M derived: sum of 4 quarters · filed 2020-03-16 | |
| 2018-03-31 | -$4.08M 10-Q · filed 2019-05-10 | -$9.13M derived: sum of 2 quarters · filed 2020-03-16 | -$15.90M derived: sum of 3 quarters · filed 2020-03-16 | -$20.88M derived: sum of 4 quarters · filed 2020-03-16 | |
| 2017-12-31 | -$5.05M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$11.82M derived: sum of 2 quarters · filed 2020-03-16 | -$16.80M derived: sum of 3 quarters · filed 2020-03-16 | -$22.66M 10-K · filed 2020-03-16 | -$22.93M 10-K · filed 2018-03-16 |
| 2017-09-30 | -$6.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$11.75M derived: sum of 2 quarters · filed 2018-11-09 | -$17.61M 10-Q · filed 2018-11-09 | -$21.00M derived: sum of 4 quarters · filed 2019-03-18 | |
| 2017-06-30 | -$4.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$10.84M 10-Q · filed 2018-08-09 | -$14.23M derived: sum of 3 quarters · filed 2019-03-18 | ||
| 2017-03-31 | -$5.86M 10-Q · filed 2018-05-10 | -$9.25M derived: sum of 2 quarters · filed 2019-03-18 | |||
| 2016-12-31 | -$3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$13.01M 10-K · filed 2019-03-18 | |||
| 2016-09-30 | -$9.62M 10-Q · filed 2017-11-14 | ||||
| 2014-09-30 | -$140.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | -$384.00K derived: sum of 2 quarters · filed 2014-11-14 | -$509.00K 10-Q · filed 2014-11-14 | -$983.00K derived: sum of 4 quarters · filed 2014-11-14 | |
| 2014-06-30 | -$244.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | -$369.00K 10-Q · filed 2014-08-14 | -$843.00K derived: sum of 3 quarters · filed 2014-08-14 | -$1.76M derived: sum of 4 quarters · filed 2014-11-14 | |
| 2014-03-31 | -$125.00K 10-Q · filed 2014-05-12 | -$599.00K derived: sum of 2 quarters · filed 2014-05-12 | -$1.51M derived: sum of 3 quarters · filed 2014-11-14 | $222.00K derived: sum of 4 quarters · filed 2014-11-14 | |
| 2013-12-31 | -$474.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-26 | -$1.39M derived: sum of 2 quarters · filed 2014-11-14 | $347.00K derived: sum of 3 quarters · filed 2014-11-14 | $1.00K 10-K · filed 2014-03-26 | |
| 2013-09-30 | -$916.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $821.00K derived: sum of 2 quarters · filed 2014-11-14 | $475.00K 10-Q · filed 2014-11-14 | -$1.14M derived: sum of 4 quarters · filed 2014-11-14 | |
| 2013-06-30 | $1.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $1.39M 10-Q · filed 2014-08-14 | -$225.00K derived: sum of 3 quarters · filed 2014-08-14 | -$707.00K derived: sum of 4 quarters · filed 2014-08-14 | |
| 2013-03-31 | -$346.00K 10-Q · filed 2014-05-12 | -$1.96M derived: sum of 2 quarters · filed 2014-05-12 | -$2.44M derived: sum of 3 quarters · filed 2014-05-12 | -$3.22M derived: sum of 4 quarters · filed 2014-05-12 | |
| 2012-12-31 | -$1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-26 | -$2.10M derived: sum of 2 quarters · filed 2014-03-26 | -$2.87M derived: sum of 3 quarters · filed 2014-03-26 | -$3.96M 10-K · filed 2014-03-26 | |
| 2012-09-30 | -$482.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | -$1.26M derived: sum of 2 quarters · filed 2013-11-14 | -$2.34M 10-Q · filed 2013-11-14 | -$4.30M derived: sum of 4 quarters · filed 2013-11-14 | |
| 2012-06-30 | -$775.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | -$1.86M 10-Q · filed 2013-08-14 | -$3.82M derived: sum of 3 quarters · filed 2013-08-14 | -$6.82M derived: sum of 4 quarters · filed 2013-08-14 | |
| 2012-03-31 | -$1.08M 10-Q · filed 2013-05-15 | -$3.05M derived: sum of 2 quarters · filed 2013-05-15 | -$6.04M derived: sum of 3 quarters · filed 2013-05-15 | -$7.85M derived: sum of 4 quarters · filed 2013-05-15 | |
| 2011-12-31 | -$1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-20 | -$4.96M derived: sum of 2 quarters · filed 2013-03-20 | -$6.77M derived: sum of 3 quarters · filed 2013-03-20 | -$7.61M 10-K · filed 2013-03-20 | |
| 2011-09-30 | -$3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-14 | -$4.81M derived: sum of 2 quarters · filed 2012-11-14 | -$5.64M 10-Q · filed 2012-11-14 | -$7.36M derived: sum of 4 quarters · filed 2012-11-14 | |
| 2011-06-30 | -$1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | -$2.65M 10-Q · filed 2012-08-14 | -$4.36M derived: sum of 3 quarters · filed 2012-08-14 | -$5.68M derived: sum of 4 quarters · filed 2012-08-14 | |
| 2011-03-31 | -$837.00K 10-Q · filed 2012-05-15 | -$2.55M derived: sum of 2 quarters · filed 2012-05-15 | -$3.87M derived: sum of 3 quarters · filed 2012-05-15 | ||
| 2010-12-31 | -$1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-23 | -$3.03M derived: sum of 2 quarters · filed 2012-03-23 | -$6.86M 10-K · filed 2012-03-23 | ||
| 2010-09-30 | -$1.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | -$5.14M 10-Q · filed 2011-11-14 | |||
| 2010-06-30 | -$3.83M 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |